You are here

Responses

Article menu
Emerging technologies, pharmacology and therapeutics
Artificial intelligence for diabetic retinopathy in low-income and middle-income countries: a scoping review
Compose a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on: 7 March 2024
    ARTIFICIAL INTELLIGENCE RED FLAGS IN DIABETIC RETINOPATHY SCREENING: FAST IS SAFE
    • ROBERTO PERILLI, HEAD, TERRITORIAL OPHTHALMOLOGY LOCAL HEALTH SERVICE, PESCARA, ITALY

    The Authors provide a thorough examination of a wide series of items related to AI in DR screening, including medico-legal issues, still under way of definition worldwide. Most articles strengthen reliability data, mainly useful to diabetologists facing DR screening, being provided with a suggestion (usually green or red flags) by the AI system. In my opinion, the workflow following a red flag has to be well-specified yet: some systems correctly suggest that red flagged patients follow a preferred pathway for a human examination, but the term "preferred" may vary owing to local organisational issues, mainly in LMICs. In my opinion and experience, one must keep in mind that red flags don't inform about how impending a vision loss can be: sometimes, bleeding of a correctly recognized proliferation, or reaching the fovea by correctly identified fluid and exudates approaching it, is a matter of hours. In such cases, missing the need for speed can worsen patients' sight and raise not-yet-defined medico-legal issues. So, I believe it would be safe to obtain an immediate ophthalmologist's or trained diabetologist's examination of all red-flagged images, what is nowadays made really easy by telemedicine.

    Conflict of Interest:
    None declared.